The Importance of Sleep Quality and the Blood-brain Barrier in Cognitive Disorders and Alzheimer's Disease
調査の概要
詳細な説明
The aim of our study is the analysis of sleep phases and quality as well as the detection of respiratory pauses in subjects with cognitive disorder. To assess whether sleep quality is associated with the blood-brain barrier and Alzheimer's disease, which may be indicative of an early, non-invasively measurable change in brain activity in the early stages of Alzheimer's disease.
Sleep quality impairment is a known risk factor for memory impairment. There is increasing evidence of a link between measurable sleep parameters, in particular a reduction of slow waves of deep sleep in cognitive deficits. Also, breathing pauses during sleep are associated with increased daytime sleepiness and cognitive impairment. This observational study is intended to establish a possible link between subjective memory disturbances and altered sleep quality or respiratory breaks during sleep. In the run-up to this study, they performed a special MRI scan of the head and a lumbar puncture (removal of nerve water) in a different context. The aim of this imaging study and the new biomarker in brain water was to investigate the function of the blood-brain barrier that occurs in Alzheimer's disease. The results of the studies on the quality of sleep should be evaluated in the context of this study in connection with the findings of the MRI examination and lumbar puncture.
研究の種類
連絡先と場所
研究場所
-
-
-
Berlin、ドイツ、10117
- Charité Universitätsmedizin Berlin
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
研究計画
研究はどのように設計されていますか？
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Mild cognitive impairment
Individuals who show deficits in neuropsychological test procedures but who do not exhibit substantial problems in daily life.
Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
|
Diagnostic Test: Contrast agentenhanced MRI using Gadovist by using the contrast agent Gadovist we aim to visualize the blood-brain barrier.
Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid.
And sleep quality measurement with a polysomnography.
|
|
Dementia due to Alzheimer's disease
Individuals diagnosed with dementia due to Alzheimer's disease by relying on anamnesis, neuropsychological test results, results of MRI and biomarkers found in the cerebrospinal fluid.
Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
|
Diagnostic Test: Contrast agentenhanced MRI using Gadovist by using the contrast agent Gadovist we aim to visualize the blood-brain barrier.
Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid.
And sleep quality measurement with a polysomnography.
|
|
Healthy controls
Healthy controls recruited through public advertisement.
|
Diagnostic Test: Contrast agentenhanced MRI using Gadovist by using the contrast agent Gadovist we aim to visualize the blood-brain barrier.
Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid.
And sleep quality measurement with a polysomnography.
|
|
Siblings of people with Alzheimer's dementia
Siblings of people with Alzheimer's dementia recruited through public advertisement
|
Diagnostic Test: Contrast agentenhanced MRI using Gadovist by using the contrast agent Gadovist we aim to visualize the blood-brain barrier.
Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid.
And sleep quality measurement with a polysomnography.
|
|
Subjective cognitive decline
Individuals who subjectively experience cognitive decline but do not show deficits in age-, sex- and education-normed neuropsychological test results.
Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
|
Diagnostic Test: Contrast agentenhanced MRI using Gadovist by using the contrast agent Gadovist we aim to visualize the blood-brain barrier.
Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid.
And sleep quality measurement with a polysomnography.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Marker of blood-brain dysfunction using MRI
時間枠：1 day
|
Dynamic T1 contrast enhanced sequence using Gadovist
|
1 day
|
|
Markers of blood-brain dysfunction using CSF
時間枠：1 day
|
Platelet-derived growth factor receptor-β in CSF
|
1 day
|
|
Sleep quality measurement
時間枠：2 day
|
Polysomnography
|
2 day
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
アルツハイマー病の臨床試験
-
Peking University Third Hospital招待による登録
-
University of California, Los Angeles募集アルツハイマー病 | 認知症アルツハイマー型 | Alzheimer＆amp;＃39; s病（AD） | アルツハイマー&Amp;Amp;#39;病 | 軽度アルツハイマー&Amp;Amp;#39;s病 | 中等度アルツハイマー&Amp;Amp;#39;s病 | アルツハイマー型認知症アメリカ
-
Baylor College of Medicine募集
-
HuidaGene Therapeutics Co., Ltd.募集
-
Hemab ApSPSI CRO募集フォン・ヴィレブランド病（VWD） | フォン・ヴィレブランド病 (VWD)、タイプ 1 | フォンウィルブランド病（VWD）、タイプ2 | Von Willebrand Disease（VWD）、タイプ3 | フォン・ウィルブランド病、タイプ2a | Von Willebrand病、タイプ2M | Von Willebrand病、タイプ2Nアメリカ, イギリス, オーストラリア
-
Adelphi Values LLCBlueprint Medicines Corporation完了肥満細胞性白血病 (MCL) | 攻撃的な全身性肥満細胞症 (ASM) | SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD) | くすぶり全身性肥満細胞症 (SSM) | 無痛性全身性肥満細胞症 (ISM) ISM サブグループが完全に募集されましたアメリカ
Diagnostic Testの臨床試験
-
London School of Hygiene and Tropical MedicineHealthNet TPO; Health Protection and Research Organisation; Medical Emergency Relief International完了
-
The First Hospital of Jilin University招待による登録超音波ガイド付き | カテーテル法、中心静脈中国
-
University Hospital Tuebingen募集
-
Norwegian Institute of Public HealthStatistics Norway; Society of Interventional Oncology完了
-
PATHUnited States Agency for International Development (USAID); Kintampo Health Research Centre,...完了